Navigation Links
Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
Date:12/14/2009

DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine. BG Medicine is seeking regulatory clearance in the United States of the BGM Galectin-3 kit for clinical use in patients with heart failure.

Galectins are a family of proteins that play an important role in organ fibrosis, and galectin-3 has been shown to play an important role in the development and progression of heart failure in animal and human studies. Heart failure is a common, complex, and serious medical condition that affects approximately six (6) million people in the U.S. alone. Once diagnosed, the prognosis is poor, with approximately 50% surviving for more than five years.

"We are extremely pleased to extend our collaboration with BG Medicine to include the manufacturing of the BGM Galectin-3 kit," said Douglass Simpson, Corgenix President and Chief Executive Officer. "BG Medicine is bringing cutting edge technology and science to the cardiology market and we look forward to a long-term relationship."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect", or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
6. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
7. Personalized Medicine - The Genomic Revolution in Cardiac Care
8. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 One of ... has announced the formation of a new biotechnology company, Noxopharm Limited ... $6m in an IPO and to list on the ASX. ... candidate, NOX66, ready to enter a Phase 1 clinical study later ... designed to address one of the biggest problems facing cancer patients ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... edge technology to revolutionize the emergency ambulance transport experience for the millions of ... of how Uber has disrupted the taxi industry through the use of technology. ...
Breaking Medicine News(10 mins):